A Lazo-Langner

Summary

Publications

  1. ncbi Standard-intensity vs low-dose anticoagulation for long-term management of patients with venous thromboembolism
    Alejandro Lazo-Langner
    The Ottawa Hospital, Department of Epidemiology and Community Medicine, University of Ottawa
    Clin Adv Hematol Oncol 3:877-9. 2005
  2. ncbi Therapeutic plasma exchange in Mexico: experience from a single institution
    Alejandro Lazo-Langner
    Department of Hematology Oncology, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Vasco de Quiroga 15, Tlalpan 14000, Mexico City, D F Mexico
    Am J Hematol 70:16-21. 2002
  3. ncbi Platelet satellitism, spurious neutropenia, and cutaneous vasculitis: casual or causal association?
    Alejandro Lazo-Langner
    Hematology and Oncology Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico D F, Mexico
    Am J Hematol 70:246-9. 2002
  4. ncbi The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials
    A Lazo-Langner
    Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
    J Thromb Haemost 5:729-37. 2007
  5. ncbi Study of Octaplex dosing accuracy: an in vitro analysis
    Christopher J Patriquin
    Department of Medicine, University of Western Ontario, London, Ontario, Canada
    Thromb Haemost 107:248-52. 2012
  6. ncbi Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial
    M A Rodger
    Ottawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada
    J Thromb Haemost 5:1600-6. 2007
  7. ncbi Ambulatory management of pulmonary embolism: a pragmatic evaluation
    M J Kovacs
    Division of Hematology, Department of Medicine, University of Western Ontario, London, ON, Canada
    J Thromb Haemost 8:2406-11. 2010
  8. ncbi Moderate and severe neutropenia in patients with systemic lupus erythematosus
    D Martinez-Baños
    Department of Haematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
    Rheumatology (Oxford) 45:994-8. 2006
  9. ncbi The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene
    Alejandro Lazo-Langner
    Division of Hematology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario Canada
    Blood 108:4052-8. 2006
  10. ncbi [Sticky platelet syndrome]
    Alejandro Lazo-Langner
    Rev Invest Clin 56:103-4; author reply 105. 2004

Collaborators

Detail Information

Publications12

  1. ncbi Standard-intensity vs low-dose anticoagulation for long-term management of patients with venous thromboembolism
    Alejandro Lazo-Langner
    The Ottawa Hospital, Department of Epidemiology and Community Medicine, University of Ottawa
    Clin Adv Hematol Oncol 3:877-9. 2005
  2. ncbi Therapeutic plasma exchange in Mexico: experience from a single institution
    Alejandro Lazo-Langner
    Department of Hematology Oncology, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Vasco de Quiroga 15, Tlalpan 14000, Mexico City, D F Mexico
    Am J Hematol 70:16-21. 2002
    ..Our complication rate is similar to that reported by others. Careful selection of patients and protocols is crucial to achieve maximum benefit from TPE programs in countries where plasmapheresis facilities are not widely available...
  3. ncbi Platelet satellitism, spurious neutropenia, and cutaneous vasculitis: casual or causal association?
    Alejandro Lazo-Langner
    Hematology and Oncology Department, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico D F, Mexico
    Am J Hematol 70:246-9. 2002
    ....
  4. ncbi The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials
    A Lazo-Langner
    Division of Hematology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
    J Thromb Haemost 5:729-37. 2007
    ..Low-molecular-weight heparins (LMWH) have an antitumor effect in vitro and in experimental animal models of malignancy. Retrospective data suggest that it might improve survival in cancer patients...
  5. ncbi Study of Octaplex dosing accuracy: an in vitro analysis
    Christopher J Patriquin
    Department of Medicine, University of Western Ontario, London, Ontario, Canada
    Thromb Haemost 107:248-52. 2012
    ..5 but factors were not uniformly >0.50 IU until 2,000 IU, and not >1.00 IU until 3,000 IU. This suggests that INR correction alone may not accurately reflect factor activity, and lends support for weight-based dosing...
  6. ncbi Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial
    M A Rodger
    Ottawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada
    J Thromb Haemost 5:1600-6. 2007
    ..The risk of decreased bone mineral density (BMD) with prophylactic dose long-term low-molecular-weight heparin (LMWH) is unknown...
  7. ncbi Ambulatory management of pulmonary embolism: a pragmatic evaluation
    M J Kovacs
    Division of Hematology, Department of Medicine, University of Western Ontario, London, ON, Canada
    J Thromb Haemost 8:2406-11. 2010
    ..Patients diagnosed with pulmonary embolism should be considered for treatment on an outpatient basis; however, this practise is not accepted in many centers...
  8. ncbi Moderate and severe neutropenia in patients with systemic lupus erythematosus
    D Martinez-Baños
    Department of Haematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
    Rheumatology (Oxford) 45:994-8. 2006
    ..The aim of this work was to review the cases of moderate and severe neutropenia in our cohort of SLE patients in order to identify predisposing factors, clinical outcomes and related prognostic implications...
  9. ncbi The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene
    Alejandro Lazo-Langner
    Division of Hematology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario Canada
    Blood 108:4052-8. 2006
    ..We concluded that low TGF-beta1 production haplotype is a risk factor for hemodialysis access thrombosis and that in the presence of the 4G/4G PAI-1 genotype there is an additional increase in risk...
  10. ncbi [Sticky platelet syndrome]
    Alejandro Lazo-Langner
    Rev Invest Clin 56:103-4; author reply 105. 2004
  11. ncbi Methodologic pitfalls in measurement of 5-hydroxytriptamine uptake transporters in human platelets by [3H]-paroxetine binding assay
    Noé Jurado
    División de Servicios Clínicos, Instituto Nacional de Psiquiatría Ramón de la Fuente, Mexico City, DF, Mexico
    Arch Med Res 34:422-7. 2003
    ....
  12. ncbi Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjögren's syndrome
    J Abraham Simón
    Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Vasco de Quiroga 15, Tlalpan 14000, Mexico City, DF, Mexico
    J Clin Apher 17:44-6. 2002
    ..We report the case of a patient with primary Sjögren's syndrome presenting as hyperviscosity syndrome who was successfully treated with therapeutic plasma exchange...